» Articles » PMID: 35833631

Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release

Overview
Journal Bioconjug Chem
Specialty Biochemistry
Date 2022 Jul 14
PMID 35833631
Authors
Affiliations
Soon will be listed here.
Abstract

Conjugation of therapeutic payloads to biologics including antibodies and albumin can enhance the selectively of drug delivery to solid tumors. However, achieving activity in tumors while avoiding healthy tissues remains a challenge, and payload activity in off-target tissues can cause toxicity for many such drug-conjugates. Here, we address this issue by presenting a drug-conjugate linker strategy that releases an active therapeutic payload upon exposure to ionizing radiation. Localized X-ray irradiation at clinically relevant doses (8 Gy) yields 50% drug (doxorubicin or monomethyl auristatin E, MMAE) release under hypoxic conditions that are traditionally associated with radiotherapy resistance. As proof-of-principle, we apply the approach to antibody- and albumin-drug conjugates and achieve >2000-fold enhanced MMAE cytotoxicity upon irradiation. Overall, this work establishes ionizing radiation as a strategy for spatially localized cancer drug delivery.

Citing Articles

Localized In Vivo Prodrug Activation Using Radionuclides.

Quintana J, Jiang F, Kang M, Valladolid Onecha V, Konik A, Qin L J Nucl Med. 2025; 66(1):91-97.

PMID: 39753366 PMC: 11705795. DOI: 10.2967/jnumed.124.268559.


Targeted Radionuclide Therapy Activates Prodrugs for Treating Metastasis.

Guo Z, Wang X, Han Y, Shen S, Tian P, Hu Y ACS Cent Sci. 2024; 10(12):2321-2330.

PMID: 39735312 PMC: 11672548. DOI: 10.1021/acscentsci.4c01369.


Extended Pharmacokinetics Improve Site-Specific Prodrug Activation Using Radiation.

Quintana J, Kang M, Hu H, Ng T, Wojtkiewicz G, Scott E ACS Cent Sci. 2024; 10(7):1371-1382.

PMID: 39071065 PMC: 11273447. DOI: 10.1021/acscentsci.4c00354.


Sustained and Localized Drug Depot Release Using Radiation-Activated Scintillating Nanoparticles.

Kang M, Quintana J, Hu H, Teixeira V, Olberg S, Banla L Adv Mater. 2024; 36(23):e2312326.

PMID: 38389502 PMC: 11161319. DOI: 10.1002/adma.202312326.


Recent advances in drug delivery and targeting for the treatment of pancreatic cancer.

Pramanik N, Gupta A, Ghanwatkar Y, Mahato R J Control Release. 2024; 366:231-260.

PMID: 38171473 PMC: 10922996. DOI: 10.1016/j.jconrel.2023.12.053.


References
1.
Ng T, Gunda V, Li R, Prytyskach M, Iwamoto Y, Kohler R . Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer. Radiology. 2020; 298(1):123-132. PMC: 7771993. DOI: 10.1148/radiol.2020201791. View

2.
Nia H, Munn L, Jain R . Physical traits of cancer. Science. 2020; 370(6516). PMC: 8274378. DOI: 10.1126/science.aaz0868. View

3.
Brunt A, Haviland J, Wheatley D, Sydenham M, Alhasso A, Bloomfield D . Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020; 395(10237):1613-1626. PMC: 7262592. DOI: 10.1016/S0140-6736(20)30932-6. View

4.
Applegate K, Besson S, Matov A, Bagonis M, Jaqaman K, Danuser G . plusTipTracker: Quantitative image analysis software for the measurement of microtubule dynamics. J Struct Biol. 2011; 176(2):168-84. PMC: 3298692. DOI: 10.1016/j.jsb.2011.07.009. View

5.
Wang Y, Giaccone G . Challenges in cancer molecular targets and therapeutics. Front Oncol. 2012; 1:4. PMC: 3356016. DOI: 10.3389/fonc.2011.00004. View